Related Experiment Video
Updated: Jan 9, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
[Tuberculosis Risk and Efficacy of Latent Tuberculosis Infection Treatment among Participants of National Latent
Hyung Woo Kim1, Jinsoo Min2, Ju Sang Kim1
1가톨릭대학교 인천성모병원 호흡기내과.
Abstract:
The study aim was to investigate the natural history of latent tuberculosis infection (LTBI) and the efficacy of LTBI treatment among participants in the national LTBI screening program. Individuals who underwent an interferon-gamma release assay (IGRA) between 2017 and 2020 were included, and tuberculosis (TB) development was investigated until April 2021. Cox proportional hazards models were used to investigate the risk factors affecting TB incidence among IGRA-negative and IGRA-positive individuals who did not undergo treatment. Additionally, the numbers needed to treat (NNT), stratified by age and interferon levels, were calculated among IGRA-positive individuals who did not undergo treatment and those who completed treatment. A comparison with contacts enrolled within the same period was performed. A total of 1,120,948 participants were included and 798 TB cases were identified. After adjusting for age, sex, history of TB exposure, and high-risk TB conditions, higher interferon levels were associated with a higher risk of TB incidence. This trend was particularly prominent in younger age groups; it was not observed in older age groups. The tendency toward a lower NNT among younger IGRA-positive individuals with higher interferon levels was observed among participants of the national screening program and contacts. Overall, a higher NNT was observed among participants of the national screening program than among contacts. However, among study participants with higher interferon levels who were under the age of 35 years, an NNT comparable to that of contacts was observed. Stratifying TB risk according to age and interferon levels could lead to more efficient LTBI screening and treatment on a national scale. Further research is warranted to validate this strategy.
More Related Videos
10:04Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
10:29A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...